Lipoprotein(a): a genetic marker for cardiovascular disease and target for emerging therapies
| Autor: | Arturo Cesaro, Matteo Conte, Elisabetta Moscarella, Martina Caiazza, Emanuele Monda, Silvio Coletta, Felice Gragnano, Paolo Calabrò, Alessandra Schiavo, Giuseppe Limongelli, Fabio Fimiani, Carmine Riccio, Marcello Arca, Laura D'Erasmo |
|---|---|
| Přispěvatelé: | Cesaro, Arturo, Schiavo, Alessandra, Moscarella, Elisabetta, Coletta, Silvio, Conte, Matteo, Gragnano, Felice, Fimiani, Fabio, Monda, Emanuele, Caiazza, Martina, Limongelli, Giuseppe, D'Erasmo, Laura, Riccio, Carmine, Arca, Marcello, Calabrò, Paolo |
| Rok vydání: | 2020 |
| Předmět: |
Genetic Markers
Apolipoprotein B Disease 030204 cardiovascular system & hematology Bioinformatics law.invention Coronary artery disease 03 medical and health sciences Lp(a) cardiovascular risk metabolism therapy 0302 clinical medicine Randomized controlled trial Risk Factors law medicine Humans 030212 general & internal medicine Risk factor biology business.industry Disease Management General Medicine Lipoprotein(a) medicine.disease Cardiovascular Diseases Genetic marker biology.protein Cardiology and Cardiovascular Medicine business Lipoprotein |
| Zdroj: | Journal of Cardiovascular Medicine. 22:151-161 |
| ISSN: | 1558-2035 1558-2027 |
| DOI: | 10.2459/jcm.0000000000001077 |
| Popis: | Lipoprotein(a) [Lp(a)] is an established cardiovascular risk factor, and growing evidence indicates its causal association with atherosclerotic disease because of the proatherogenic low-density lipoprotein (LDL)-like properties and the prothrombotic plasminogen-like activity of apolipoprotein(a) [apo(a)]. As genetics significantly influences its plasma concentration, Lp(a) is considered an inherited risk factor of atherosclerotic cardiovascular disease (ASCVD), especially in young individuals. Moreover, it has been suggested that elevated Lp(a) may significantly contribute to residual cardiovascular risk in patients with coronary artery disease and optimal LDL-C levels. Nonetheless, the fascinating hypothesis that lowering Lp(a) could reduce the risk of cardiovascular events - in primary or secondary prevention - still needs to be demonstrated by randomized clinical trials. To date, no specific Lp(a)-lowering agent has been approved for reducing the lipoprotein levels, and current lipid-lowering drugs have limited effects. In the future, emerging therapies targeting Lp(a) may offer the possibility to further investigate the relation between Lp(a) levels and cardiovascular outcomes in randomized controlled trials, ultimately leading to a new era in cardiovascular prevention. In this review, we aim to provide an updated overview of current evidence on Lp(a) as well as currently investigated therapeutic strategies that specifically address the reduction of the lipoprotein. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|